RSS | Login | Register

ELIDEL

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ELIDEL to:

Generic Name for ELIDEL

Pimecrolimus 1%; crm.

Legal Classification:

Pharmacological Class for ELIDEL

Immunomodulator.

Manufacturer of ELIDEL

Novartis Pharmaceuticals Corp

Indications for ELIDEL

Second-line therapy: for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients when other topical therapies are inadvisable or ineffective.

Adults and Children:

<2 years: not recommended. ≥2 years: apply to affected area(s) twice daily. Do not occlude.

Warnings/Precautions for ELIDEL

Clear infections at treatment site before starting. Netherton's syndrome, generalized erythroderma, malignant or pre-malignant skin conditions: not recommended. Varicella zoster. Eczema herpeticum. Herpes simplex. Consider discontinuing if lymphadenopathy of unknown etiology or acute infectious mononucleosis occurs. Consider discontinuing until warts clear if skin papillomas worsen or are unresponsive. Avoid sun, UV light. Reevaluate if no improvement after 6 weeks. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for ELIDEL

Caution with CYP3A inhibitors in widespread and/or erythrodermic disease.

Adverse Reactions for ELIDEL

Local reactions (eg, burning), nasopharyngitis, pyrexia, cough, headache, others; rare: malignancy (eg, skin, lymphoma).

How is ELIDEL supplied?

Crm—30g, 60g, 100g

Related Disease:

Atopic dermatitis

Dermatological conditions, miscellaneous

Asclera injection available for sclerotherapy

July 15, 2010

BioForm Medical has launched Asclera (polidocanol injection), a sclerotherapy treatment.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

FDA issues warning letters for fat eliminating products

April 07, 2010

The FDA has issued warning letters to six medical spas for making false or misleading statements on their websites about drugs they claim will eliminate fat in a procedure called "lipodissolve," or for otherwise misbranding lipodissolve products.

EvoLife products available for cancer patients undergoing chemotherapy and radiotherapy

March 31, 2010

EvoLife Laboratories has launched its product line of skin, oral, nail, hair, hygiene care for cancer patients undergoing chemotherapy and radiotherapy.

Asclera approved for treatment of varicose veins

March 31, 2010

The FDA has approved Asclera (polidocanol injection, from BioForm Medical) for the treatment of small types of abnormally swollen or twisted veins called varicose veins.